![](/images/graphics-bg.png)
Randomized Phase II Study of Docetaxel plus Personalized Peptide Vaccination versus Docetaxel plus Placebo for Patients with Previously Treated Advanced Wild Type EGFR Non-Small-Cell Lung Cancer
المؤلفون المشاركون
Nakanishi, Yoichi
Yamada, Akira
Kakuma, Tatsuyuki
Noguchi, Masanori
Takayama, Koichi
Sugawara, Shunichi
Saijo, Yasuo
Maemondo, Makoto
Sato, Atsushi
Takamori, Shinzo
Harada, Taishi
Sasada, Tetsuro
Kishimoto, Junji
Itoh, Kyogo
المصدر
Journal of Immunology Research
العدد
المجلد 2016، العدد 2016 (31 ديسمبر/كانون الأول 2016)، ص ص. 1-7، 7ص.
الناشر
Hindawi Publishing Corporation
تاريخ النشر
2016-05-04
دولة النشر
مصر
عدد الصفحات
7
التخصصات الرئيسية
الملخص EN
Objectives.
To evaluate the efficacy and safety of personalized peptide vaccination (PPV) combined with chemotherapy for patients with previously treated advanced non-small-cell lung cancer (NSCLC).
Patients and Methods.
Previously treated PS0-1 patients with IIIB/IV EGFR (epidermal growth factor receptor) wild genotype NSCLC were randomly assigned to docetaxel (60 mg/m2 on Day 1) plus PPV based on preexisting host immunity or docetaxel plus placebo.
Docetaxel administration was repeated every 3 weeks until disease progression.
Personalized peptides or placebo was injected subcutaneously weekly in the first 8 weeks and biweekly in subsequent 16 weeks.
The primary efficacy endpoint was progression-free survival (PFS).
Results.
PPV related toxicity was grade 2 or less skin reaction.
The median PFS for placebo arm and PPV arm was 52 days and 59 days, respectively.
There was no significant difference between two arms by log-rank test ( p = 0.42 ).
Interestingly, PFS and overall survival (OS) in humoral immunological responder were significantly longer than those in nonresponder.
Conclusion.
PPV did not improve the survival in combination with docetaxel for previously treated advanced NSCLC.
However, PPV may be efficacious for the humoral immunological responders and a further clinical investigation is needed.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Takayama, Koichi& Sugawara, Shunichi& Saijo, Yasuo& Maemondo, Makoto& Sato, Atsushi& Takamori, Shinzo…[et al.]. 2016. Randomized Phase II Study of Docetaxel plus Personalized Peptide Vaccination versus Docetaxel plus Placebo for Patients with Previously Treated Advanced Wild Type EGFR Non-Small-Cell Lung Cancer. Journal of Immunology Research،Vol. 2016, no. 2016, pp.1-7.
https://search.emarefa.net/detail/BIM-1108722
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Takayama, Koichi…[et al.]. Randomized Phase II Study of Docetaxel plus Personalized Peptide Vaccination versus Docetaxel plus Placebo for Patients with Previously Treated Advanced Wild Type EGFR Non-Small-Cell Lung Cancer. Journal of Immunology Research No. 2016 (2016), pp.1-7.
https://search.emarefa.net/detail/BIM-1108722
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Takayama, Koichi& Sugawara, Shunichi& Saijo, Yasuo& Maemondo, Makoto& Sato, Atsushi& Takamori, Shinzo…[et al.]. Randomized Phase II Study of Docetaxel plus Personalized Peptide Vaccination versus Docetaxel plus Placebo for Patients with Previously Treated Advanced Wild Type EGFR Non-Small-Cell Lung Cancer. Journal of Immunology Research. 2016. Vol. 2016, no. 2016, pp.1-7.
https://search.emarefa.net/detail/BIM-1108722
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references
رقم السجل
BIM-1108722
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
![](/images/ebook-kashef.png)
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر
![](/images/kashef-image.png)